Catalent begins supply of Abilify antipsychotic drug to Otsuka Pharma

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

Catalent has started supplying its antipsychotic drug, Abilify, an orally disintegrating tablet (ODT) to Otsuka Pharmaceutical.

Abilify ODT, which utilizes Catalent’s Zydis fast dissolve drug delivery technology, is designed to improve manic symptoms associated with bipolar disorder as well as to treat schizophrenia.

Catalent said to support the increasing demand for Zydis ODT formulations, it is making multi-million dollar investments in Swindon, UK.

Catalent modified release technology business president Ian Muir said the company’s Zydis fast dissolve technology has provided a tablet that is very palatable, and disintegrates within seconds in the mouth, making it very easy to take.

“As patient medication compliance is critical for those requiring antipsychotic therapies, Otsuka believes this new formulation will be of great assistance to patients in Japan,” Muir added.

“Abilify® OD is the 8th drug approved and launched in Japan, using Catalent’s Zydis ODT.” Catalent president Hans-Joachim Rohe said the company has seen an increasing number of customers specifically seeking truly rapid disintegration and superior palatability in order to differentiate their products in Japan’s competitive market.

“In this regard, Zydis ODT can excel over competing alternatives such as loosely compressed tablets,” Rohe added.

Latest stories

Related stories

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back